WF
Interim Chief Financial Officer
Get the full picture
Sign in to uncover key details.
Annovis Bio
Manufacturing · Pennsylvania, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
101 Lindenwood Dr Ste 225, Malvern, Penn...Phone Number
(484) 875-3192Website
www.annovisbio.comRevenue
<$5 MillionStock Symbol
ANVSIndustry
About Annovis Bio
Annovis Bio, Inc. is a clinical-stage drug platform company headquartered in Berwyn, Pennsylvania, focused on developing therapies for neurodegenerative diseases. Its lead candidate, buntanetap, is being studied in Phase 3 trials for Alzheimer's and Parkinson's disease. The company also develops treatments targeting traumatic brain injury, stroke, and advanced Alzheimer's-related cognitive decline, aiming to restore nerve cell function and improve brain health outcomes for patients with chronic and acute neurodegeneration.Explore more
Annovis Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Annovis Bio
Compare insights from companies similar to Annovis Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
11-50
Private
<$5M
2005
CL
Cynthia LevinthalPrincipal Consultant. Neural Stem Cell Therapies. Clinical Trials
Annovis Bio Tech Stack
A closer look at the technologies used by Annovis Bio
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Annovis Bio
Sign Up For FreeTo access detailed company insights
Annovis Bio, Inc. is a clinical-stage drug platform company headquartered in Berwyn, Pennsylvania, focused on developing therapies for neurodegenerative diseases. Its lead candidate, buntanetap, is being studied in Phase 3 trials for Alzheimer's and Parkinson's disease. The company also develops treatments targeting traumatic brain injury, stroke,... Read More
